过去 90 天内没有内部人买入。最近一笔由 Elanco Animal Health Inc 披露于 2021年8月30日。
Kindred Biosciences, Inc.：高管交易动态
以下是Kindred Biosciences, Inc.高管的股票交易情况，数据经由SEC (Form 4)发布；该公司属于医疗与制药行业。Kindred Biosciences, Inc.已超过一年没有高管申报，最近一份可追溯到2021年9月13日。
完整历史始于2013年，共计41笔买入、41笔卖出。
数据来源：高管申报（SEC (Form 4)）。过往交易不代表未来收益。
该评分只在所属市场内对买入进行排名。仅在经过回测的策略范围内的交易所提供建议仓位；其他市场的信号仍处于观察状态。并非投资建议。
财务数据
财年 2020财年截至 2020年12月 · cache
- 6,000,002 股股票SEC:0000905718-21-001189:0
- 2,000 股@ US$9.250.1% 占其流量股票SEC:0001250853-21-000092:1
- 45,508,938 股@ US$9.25100.0% 占其流量股票SEC:0001104659-21-110763:0标准退出：2021年11月25日 (T+90)
- 24,928 股@ US$9.25100.0% 占其流量股票SEC:0001250853-21-000087:0
- 1,709,271 股@ US$9.2595.6% 占其流量股票SEC:0001250853-21-000092:0
- 78,613 股@ US$9.25100.0% 占其流量股票SEC:0001250853-21-000091:0
- 145,835 股@ US$9.25100.0% 占其流量股票SEC:0001250853-21-000090:0
- 64,306 股@ US$9.25100.0% 占其流量股票SEC:0001250853-21-000089:0
- 40,000 股@ US$9.211.6% 占其流量股票SEC:0001250853-21-000081:1
- 320,000 股0股票SEC:0001250853-21-000081:0
- 40,000 股@ US$9.1772.2% 占其流量股票SEC:0001250853-21-000071:0
- 40,000 股@ US$9.18172.2% 占其流量股票SEC:0001250853-21-000066:0
- 345,383 股@ US$6.955.5% 占其流量股票SEC:0000905718-21-000762:1
- 69,600 股@ US$6.7973100.0% 占其流量股票SEC:0000905718-21-000762:0
- 8,396 股@ US$0.320.1% 占其流量股票SEC:0001250853-21-000039:0
- 8,396 股@ US$5.0021.7% 占其流量股票SEC:0001250853-21-000039:1
- 5 股@ US$0.320.0% 占其流量股票SEC:0001250853-21-000035:0
- 5 股@ US$5.000.0% 占其流量股票SEC:0001250853-21-000035:1
- 4,622 股@ US$0.320.1% 占其流量股票SEC:0001250853-21-000035:2
- 4,622 股@ US$5.000.9% 占其流量股票SEC:0001250853-21-000035:3
- 6,582 股@ US$5.000.1% 占其流量股票SEC:0001250853-21-000024:1
- 12,500 股股票SEC:0001250853-21-000024:0
- 210,472 股@ US$5.252.6% 占其流量股票SEC:0000905718-21-000122:0
- 3,300 股@ US$5.070.0% 占其流量股票SEC:0000905718-21-000122:1
- 6,250 股股票SEC:0001250853-21-000022:0
168 条申报中的 25 条
About Kindred Biosciences, Inc.
Kindred Biosciences, Inc. (ticker: KIN) was a U.S.-based animal health biotechnology company that was formerly listed on the NASDAQ in the United States. Founded in 2012 and headquartered in Burlingame, California, the company focused on developing veterinary therapeutics, with an emphasis on biologic medicines for companion animals such as dogs and cats. Its strategy centered on research and development, regulatory advancement, manufacturing preparation, and, for select assets, commercial partnering. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1561743/000156174314000010/kindredbio10-k.htm?utm_source=openai))
From an operating perspective, KindredBio positioned itself as an innovation-driven developer rather than a broad animal-health distributor. Public filings indicated that its portfolio included more than 20 product candidates at one point, predominantly biologics, and that it had also achieved at least two approved products prior to its acquisition. That mix gave the company a differentiated profile within veterinary medicine, where product development, clinical evidence, and regulatory execution are central to value creation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1561743/000156174320000009/kindredbio201910-k.htm?utm_source=openai))
展开全文收起
In competitive terms, KindredBio occupied a specialized niche at the intersection of biotechnology and animal health. Its key competitive advantage was the ability to target unmet veterinary needs with biologic assets that could command higher scientific and strategic value than conventional animal-health products. While it competed indirectly with much larger global animal-health companies, its focus on companion-animal therapeutics gave it a distinct, high-science positioning. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1561743/000156174321000060/k9-knightdefinitiveproxyst.htm?utm_source=openai))
The most important recent corporate development was its acquisition by Elanco Animal Health. Elanco announced the deal in June 2021 and completed it in August 2021, paying $9.25 per share for an aggregate cash consideration of about $444 million. Following closing, KindredBio’s common stock stopped trading on the NASDAQ, and the company ceased to exist as an independent publicly listed issuer. For investors reviewing SEC Form 4 insider transactions, that historical context is essential: KIN-related filings should be understood as legacy filings from a now-acquired company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1739104/000173910421000013/elan-20210630.htm?utm_source=openai))
Overall, Kindred Biosciences was a small-cap veterinary biotech founded in 2012 in the United States, listed on the NASDAQ, and built around a biologics pipeline for companion animals. Its analytical significance lies in its specialized R&D platform, its approved-product base, and its eventual acquisition, which validated the strategic value of its animal-health assets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1561743/000156174314000010/kindredbio10-k.htm?utm_source=openai))
